Does Medicare Cover GLP-1 Medications? Semaglutide, Tirzepatide, and Your 2026 Options

Whether Medicare covers semaglutide depends on why your doctor is prescribing it, and the answer has changed significantly since 2023.

*Compounded semaglutide and compounded tirzepatide are not FDA-approved medications. This article is for educational and informational purposes only and does not constitute medical advice. Medicare coverage rules cited here reflect CMS guidance as of mid-2026 and may change. Consult your licensed healthcare provider before starting any medication, and verify coverage details with your Medicare plan directly. Individual results vary. All prescribing at Prescriva is performed by independently licensed healthcare providers.*

---

If you are enrolled in Medicare and wondering whether your plan will cover [GLP-1 medications](/resources/what-are-glp1-medications-complete-guide) like semaglutide (Ozempic, Wegovy) or tirzepatide (Mounjaro, Zepbound), the answer is more complicated than a simple yes or no.

For many Medicare beneficiaries, it comes down to one question: is the drug being prescribed for diabetes, or for weight loss? That single distinction determines whether you have coverage and how much you will pay out of pocket.

This guide explains how Medicare handles GLP-1 medications in 2026, what changed because of recent cardiovascular research, how Medicare Advantage compares to Original Medicare, and what your alternatives are if coverage falls short.

---

The Short Answer: It Depends on the Indication

Medicare Part D, which covers prescription drugs for Medicare beneficiaries, has historically operated under a provision in the Social Security Act that prohibits coverage for drugs used "for weight loss." This exclusion has been in place for decades, predating GLP-1 medications entirely.

The practical result: Medicare does not cover GLP-1 medications when they are prescribed solely for weight management. It does cover them when they are prescribed to manage type 2 diabetes or, more recently, to reduce cardiovascular risk in eligible patients.

Here is how that plays out across the major GLP-1 drugs available in 2026:

---

Medicare Does Cover GLP-1s for Diabetes

If you have type 2 diabetes and your provider prescribes Ozempic or Rybelsus to help manage your blood sugar, that prescription falls into a covered category. Medicare Part D plans treat diabetes as a standard covered condition, and GLP-1 receptor agonists approved for diabetes are on the formularies of most major Part D plans.

Similarly, Mounjaro (tirzepatide) is FDA-approved for type 2 diabetes management and is typically covered when prescribed for that indication. Cost-sharing varies by plan and formulary tier, but a copay of $25 to $100 per month after meeting your deductible is realistic for diabetes-indicated prescriptions.

The diabetes coverage exception is meaningful for many Medicare beneficiaries who are managing both type 2 diabetes and excess weight at the same time. If your diabetes management is the primary clinical rationale and your provider documents it accordingly, GLP-1 coverage under Part D is generally available.

---

What the SELECT Trial Changed for Cardiovascular Coverage

The coverage picture shifted in late 2023, when results from the SELECT trial were published in the New England Journal of Medicine [1]. In this large randomized trial of more than 17,000 participants, weekly semaglutide (Wegovy) reduced the risk of major cardiovascular events, including heart attack, stroke, and cardiovascular death, by 20 percent compared to placebo. Crucially, none of the participants had type 2 diabetes. All had established atherosclerotic cardiovascular disease and were overweight or obese.

This was not a weight loss trial in the conventional sense. It was a cardiovascular outcomes trial that happened to use a weight management drug. The results established semaglutide as a medication with proven cardiovascular benefit, independent of its effects on blood sugar.

The Centers for Medicare and Medicaid Services (CMS) responded. In 2024, CMS issued guidance clarifying that Medicare Part D plans are permitted to cover Wegovy when it is prescribed to reduce cardiovascular risk in patients with established cardiovascular disease. This represents a meaningful expansion of coverage, but it comes with important conditions.

To qualify for this cardiovascular coverage pathway, you generally need:

• A documented history of established atherosclerotic cardiovascular disease (prior heart attack, stroke, or peripheral arterial disease)
• A prescription written with the cardiovascular risk reduction indication as the clinical rationale
• Enrollment in a Part D plan that has chosen to include Wegovy in its formulary under the CMS guidance (plans are permitted to cover it, not required to)

If you are seeking GLP-1 treatment purely for weight management without established cardiovascular disease, the standard weight loss exclusion still applies as of mid-2026.

---

Heart Failure Coverage: STEP-HFpEF

A second landmark 2023 trial, STEP-HFpEF, published in the New England Journal of Medicine, found that semaglutide significantly improved symptoms, physical limitations, and body weight in patients with heart failure with preserved ejection fraction (HFpEF) who had obesity [2]. HFpEF is one of the most common forms of heart failure and one of the hardest to treat.

CMS has recognized HFpEF as another potential coverage basis for Wegovy, though coverage implementation varies across Part D plans. If you have been diagnosed with HFpEF and your provider believes Wegovy would benefit your cardiovascular health, it is worth having your provider verify your plan's specific coverage policy and submit prior authorization documentation that emphasizes the cardiovascular indication.

---

Medicare Advantage: A Different Landscape

Medicare Advantage (Part C) plans are private insurance plans that must provide at least the same benefits as Original Medicare but can go further. Some Medicare Advantage plans have voluntarily added Wegovy to their formularies, particularly for patients who qualify under the cardiovascular coverage pathway.

Coverage under Medicare Advantage varies considerably by plan, carrier, and region. A plan in one state may cover Wegovy with a $50 copay; a plan in another state from the same carrier may not cover it at all. Additionally, Advantage plan formularies change each year during open enrollment, so coverage you have in 2026 may or may not carry into 2027.

If you are in a Medicare Advantage plan and want to know whether you have GLP-1 coverage:

1. Log into your plan's online portal and search the formulary by drug name (search both "Wegovy" and "semaglutide")
2. Call your plan's member services line directly and ask whether semaglutide is covered for cardiovascular risk reduction
3. Ask your prescribing provider to submit a formulary coverage inquiry on your behalf before starting the prescription process

---

What It Costs Without Coverage

If you do not qualify for Medicare coverage of a GLP-1 medication, or if your specific plan does not cover it, the out-of-pocket costs for branded medications are substantial.

Branded GLP-1 list prices without coverage in 2026:

• Wegovy (semaglutide for weight management): approximately $1,300 to $1,500 per month
• Zepbound (tirzepatide for weight management): approximately $1,000 to $1,200 per month
• Ozempic (semaglutide for T2D, if used off-label for weight loss without coverage): similar to Wegovy pricing

The Inflation Reduction Act of 2022 introduced an out-of-pocket cap for Medicare Part D beneficiaries, which took full effect in 2025. Under this cap, your total out-of-pocket spending on covered Part D drugs cannot exceed $2,000 per year. However, this cap applies only to drugs your plan covers. If Wegovy is not on your plan's formulary, the cap does not protect you from its full list price.

A 2025 analysis published in JAMA Health Forum estimated the fiscal impact of expanding Medicare GLP-1 coverage broadly for obesity treatment, projecting significant cost implications for the program [3]. A similar analysis in Health Affairs estimated that expanded Medicare anti-obesity medication coverage could increase annual spending by $3.1 billion to $6.1 billion [4]. These cost projections help explain why comprehensive Medicare coverage of GLP-1s for weight management has not yet passed into law, despite bipartisan support for proposals like the Treat and Reduce Obesity Act.

---

Compounded Semaglutide: The Out-of-Pocket Alternative

For Medicare beneficiaries who do not have coverage for a GLP-1 medication, compounded semaglutide is an option that many patients in this situation are exploring. It is not covered by Medicare, but the direct cash-pay cost is a fraction of the branded list price.

Compounded semaglutide is prepared by a state-licensed 503A compounding pharmacy based on an individual prescription from a licensed provider. It is not FDA-approved, which is an important distinction to understand. The FDA has not reviewed compounded semaglutide for safety, efficacy, or quality in the same way it reviewed Wegovy or Ozempic. Any legitimate provider will be transparent about this.

A few things that are important to know if you are a Medicare beneficiary considering this path:

You cannot submit it to Medicare. Compounded medications are not eligible for Medicare reimbursement. The cost is fully out-of-pocket.

It still requires a real medical evaluation. Prescriptions for compounded semaglutide require a licensed provider to evaluate your health history, medications, and appropriateness for treatment. This evaluation matters even more in older adults, who may take multiple medications with potential interactions.

Safety considerations are amplified in the 65+ population. [GLP-1 medications for older adults](/resources/glp1-medications-older-adults-over-65) require some additional attention: muscle preservation matters more, appetite suppression can accelerate unintended lean mass loss if protein intake is not actively managed, and kidney function should be considered when evaluating any new medication.

At Prescriva, compounded semaglutide starts at $169/mo on the 52-week plan ($289/mo month-to-month). This is all-inclusive: medical consultation, medication, and shipping. No separate pharmacy bills, no annual formulary changes.

---

How to Check Your Specific Medicare Coverage

Rather than assuming coverage or assuming lack of it, the most reliable path is to verify your plan directly. Here is a step-by-step approach:

1. Identify your drug: Ask your provider whether they are prescribing Ozempic, Wegovy, Mounjaro, or Zepbound, and for which indication.
2. Search the formulary: Use Medicare's online plan finder (medicare.gov) or your specific plan's member portal to search by drug name and your Medicare ID number.
3. Check the prior authorization requirements: Most Part D plans require prior authorization for specialty medications. Your provider's office should be experienced with this process.
4. Ask about the cardiovascular pathway: If you have a history of heart disease, stroke, or peripheral artery disease, ask your provider explicitly whether Wegovy would be appropriate under the cardiovascular indication. This pathway opens coverage that does not exist for obesity-only indications.
5. Consult a licensed pharmacist or your plan's Medicare coordinator: Both can help you understand your specific formulary tier, copay structure, and coverage gaps.

---

Looking Ahead: Will Medicare Coverage Expand?

The political and policy momentum around Medicare GLP-1 coverage has been building. The SELECT and STEP-HFpEF trials made a strong scientific case that semaglutide is a cardiovascular drug, not just a weight loss drug, and CMS has begun translating that science into coverage policy.

Proposals to mandate Medicare coverage of anti-obesity medications for broader populations have gained bipartisan congressional support, but as of mid-2026, no legislation requiring comprehensive coverage has passed. Coverage decisions remain at the discretion of individual Part D and Medicare Advantage plans.

For Medicare beneficiaries today, the practical options are: qualify for coverage under the cardiovascular or diabetes pathways, appeal a denial if your situation supports it, or access compounded GLP-1 treatment as a direct-pay option while the coverage landscape continues to evolve.

If you want to explore whether compounded semaglutide or tirzepatide is right for your situation, our licensed providers can evaluate your health history and help you understand what treatment looks like at [Prescriva pricing](/resources/cheapest-compounded-semaglutide-online-2026). If you are also reviewing [semaglutide insurance coverage](/resources/semaglutide-insurance-coverage) or [tirzepatide insurance coverage](/resources/tirzepatide-insurance-coverage) more broadly, those guides cover commercial plans, Medicaid, and prior authorization in more detail.

---

References

1. Lincoff AM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. *N Engl J Med.* 2023 Dec 14. PMID: 37952131

1. Kosiborod MN, et al. Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity. *N Engl J Med.* 2023 Sep 21. PMID: 37622681

1. Hwang JH, et al. Fiscal Impact of Expanded Medicare Coverage for GLP-1 Receptor Agonists to Treat Obesity. *JAMA Health Forum.* 2025 Apr 4. PMID: 40279111

1. Ippolito B, et al. Expanding Medicare Coverage Of Anti-Obesity Medicines Could Increase Annual Spending By $3.1 Billion To $6.1 Billion. *Health Aff (Millwood).* 2024 Sep. PMID: 39146500

---

*This article is not medical advice. Medicare coverage rules described here reflect publicly available CMS guidance and are subject to change. Verify your specific coverage with your Medicare plan, a licensed insurance advisor, or your healthcare provider. Compounded semaglutide is not FDA-approved. Consult your licensed healthcare provider before starting any new medication.*